Holen Sie sich die Stockscreener-App
2.23
0.00%
0.00
Handel nachbörslich:
2.27
0.04
+1.79%
Schlusskurs vom Vortag:
$2.23
Offen:
$2.21
24-Stunden-Volumen:
362.62K
Relative Volume:
0.99
Marktkapitalisierung:
$18.41M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.42M
KGV:
-0.2338
EPS:
-9.54
Netto-Cashflow:
$-7.45M
1W Leistung:
+17.37%
1M Leistung:
-76.87%
6M Leistung:
-89.58%
1J Leistung:
-67.63%
1-Tages-Spanne:
$2.07
$2.28
1-Wochen-Bereich:
$1.80
$2.315
52-Wochen-Spanne:
$1.80
$26.38
Cervomed Inc Stock (CRVO) Company Profile
Firmenname
Cervomed Inc
Sektor
Branche
Telefon
(617) 744-4400
Adresse
20 PARK PLAZA, BOSTON
Vergleichen Sie CRVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
2.23 | 18.41M | 0 | -6.42M | -7.45M | -5.6013 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-12-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-18 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-07-26 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-11-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cervomed Inc Aktie (CRVO) Neueste Nachrichten
HC Wainwright & Co. Downgrades CervoMed (CRVO) - MSN
Research Analysts Issue Forecasts for CervoMed Q1 Earnings - Defense World
CervoMed (NASDAQ:CRVO) Cut to Hold at Brookline Capital Management - Defense World
CervoMed price target lowered to $4 from $45 at Roth MKM - Yahoo Finance
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
CervoMed Awards Key Executive Stock Options in Strategic Talent Acquisition Move - StockTitan
CervoMed's dementia drug fails mid-stage trial, shares slump - MSN
Chardan Capital Downgrades CervoMed (CRVO) - MSN
What Was Behind CervoMed’s Lewy Body Disappointment? - News & Insights
CervoMed announces RewinD-LB Phase 2b did not meet primary endpoint - Yahoo Finance
Morgan Stanley cuts CervoMed to Underweight on disappointing trial results By Investing.com - Investing.com UK
CervoMed shares await clarity with open-label extension data and French Phase 2a results - Investing.com Canada
CervoMed stock downgraded to Hold as Phase 2b trial disappoints By Investing.com - Investing.com Canada
CervoMed shares rating downgraded after trial data disappoints - Investing.com
Jones Trading Downgrades CervoMed (CRVO) - MSN
CervoMed's dementia drug fails to meet mid-stage trial goals - MSN
CervoMed stock downgraded to Hold as Phase 2b trial disappoints - Investing.com
CervoMed shares rating downgraded after trial data disappoints By Investing.com - Investing.com Canada
CervoMed’s stock craters 77% after failed trial of treatment for rare brain disease - MSN
CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets - Yahoo Finance
US Small Business Optimism Hits 3-Year High As Election Results 'Signal A Major Shift' - Benzinga
CervoMed Shares Slide to All-Time Low After Study Failure - MarketWatch
CervoMed’s dementia drug fails to meet mid-stage trial goals - 1470 & 100.3 WMBD
Late-stage plans on ice as CervoMed's oral drug fails dementia study - FirstWord Pharma
CervoMed's ex-Vertex drug fails to reduce dementia symptoms in phase 2 trial - Fierce Biotech
CervoMed Inc. Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies - Marketscreener.com
CervoMed tumbles after dementia drug fails to meet mid-stage trial goals - XM
CervoMed Faces Setback in Phase 2b Trial - TipRanks
CervoMed Phase 2b Study of Neflamapimod Misses Main Endpoints - MarketWatch
CervoMed Announces Topline Data from RewinD-LB Phase 2b - GlobeNewswire
HC Wainwright Predicts CervoMed FY2024 Earnings - MarketBeat
CervoMed (NASDAQ:CRVO) Coverage Initiated at Roth Mkm - Defense World
Research Analysts Set Expectations for CervoMed Q4 Earnings - Defense World
Roth/MKM sets stock target on CervoMed, buy rating on strong trial results - Investing.com Nigeria
HC Wainwright & Co. Initiates Coverage of CervoMed (CRVO) with Buy Recommendation - MSN
CervoMed (NASDAQ:CRVO) Coverage Initiated by Analysts at Roth Mkm - MarketBeat
What is HC Wainwright's Estimate for CervoMed Q4 Earnings? - MarketBeat
CervoMed Enhances Transparency with Key Information Access - TipRanks
CervoMed (NASDAQ:CRVO) Given “Buy” Rating at D. Boral Capital - Defense World
Morgan Stanley Initiates Coverage of CervoMed (CRVO) with Overweight Recommendation - MSN
FDA grants Orphan Drug status to CervoMed's dementia drug By Investing.com - Investing.com South Africa
CervoMed’s stock rises as FDA grants orphan drug status to dementia drug - Pharmaceutical Technology
CervoMed Stock Surges On FDA Orphan Drug Nod For FTD Treatment: Retail Optimism Rekindled - MSN
CervoMed's (CRVO) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
CervoMed stock gains on FDA orphan tag (CRVO:NASDAQ) - Seeking Alpha
CervoMed Shares Rise 15% on FDA's Orphan Drug Designation for Neflamapimod - Marketscreener.com
CervoMed announces ODD granted to neflamapimod by U.S. FDA - TipRanks
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia - The Manila Times
FDA grants Orphan Drug status to CervoMed's dementia drug - Investing.com
CervoMed Announces Orphan Drug Designation Granted to - GlobeNewswire
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for - EIN News
Finanzdaten der Cervomed Inc-Aktie (CRVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):